Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II randomized double-blind trial of recombinant botulinum toxin type A for moderate to severe glabellar lines
CTR20253119Phase 2Completed
- Sponsor
- Lepu Jiantang Pharmaceutical
- Start
- Aug 2025
- Modality
- Bacterial Toxin Conjugates → Immunotoxins → Antibody Conjugates → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of JHM03 in glabellar furrowing, sponsored by Lepu Jiantang Pharmaceutical. Started Aug 2025; status: completed.
02
Drugs
JHM03
03
Conditions
glabellar furrowing
Beyond the preview
Go deeper on CTR20253119.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20253119.